{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:24:26Z","timestamp":1787772266143,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Imatinib and nilotinib are inhibitors of tyrosine kinases (TKIs) generated from the bcr-abl fusion protein, c-Kit, and platelet-derived growth factor receptors. Cutaneous adverse effects (AEs) of TKI are the most frequent non-hematological sequelae. In our case, the common molecular target raises the possibility that cross-intolerance, in which similar AEs occur with both agents, can arise. We hereby report a rare case report on cross-intolerance of cutaneous AEs of imatinib and nilotinib in chronic myeloid leukemia.<\/jats:p>","DOI":"10.4103\/idoj.idoj_229_23","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:17:55Z","timestamp":1714393075000},"page":"492-495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report"],"prefix":"10.4103","volume":"15","author":[{"given":"Meenakshi","family":"Sachdeva","sequence":"first","affiliation":[{"name":"Department of Dermatology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanti","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Dayal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijdd.ijdd_25_17","article-title":"Imatinib-induced lichen planus resolving with depigmentation","volume":"3","author":"Shah","year":"2017","journal-title":"Indian J Drugs Dermatol"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/2229-516X.149253","article-title":"Lichenoid drug eruption due to imatinib mesylate","volume":"5","author":"Bhatia","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"key":"R5-20250921","first-page":"189","article-title":"Imatinib mesylate-induced lichenoid drug eruption","volume":"99","author":"Penn","year":"2017","journal-title":"Cutis"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors \u2013A review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/idoj.IDOJ_536_20","article-title":"Imatinib-induced classical lichen planopilaris in Blaschko-linear distribution leading to cicatricial alopecia","volume":"12","author":"Thakran","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000437383","article-title":"Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"232","author":"Patel","year":"2016","journal-title":"Dermatology"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_229_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:35:26Z","timestamp":1787769326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_229_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_229_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"2023-03-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}